Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31092
Title: | Cerebral microbleeds in dementia with Lewy bodies. | Austin Authors: | Chin, Kai Sin;Hijazi, Zina;Churilov, Leonid ;Gajamange, Sanuji;Desmond, Patricia M;Villemagne, Victor L ;Rowe, Christopher C ;Yassi, Nawaf;Watson, Rosie | Affiliation: | Medicine (University of Melbourne) Department of Radiology, The Royal Melbourne Hospital, Parkville, Australia The Florey Institute of Neuroscience and Mental Health Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia Department of Medicine - the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia Department of Aged Care, The Royal Melbourne Hospital, Parkville, Australia |
Issue Date: | 12-Oct-2022 | Date: | 2022 | Publication information: | Parkinsonism & Related Disorders 2022; 104: 68-71 | Abstract: | Cerebral microbleeds (CMB) are associated with cognitive impairment and hypertensive or cerebral amyloid angiopathy. The pathophysiology and clinical significance of CMB in dementia with Lewy bodies (DLB) are not well understood. Our study aimed to investigate the prevalence of CMB in DLB and to estimate the magnitudes of their clinical associations. Twenty participants with DLB (mean age 74 ± 5 years) were included in this cross-sectional study. All participants underwent 3 T magnetic resonance imaging. CMB number and location were assessed on susceptibility-weighted imaging or quantitative susceptibility mapping. Amyloid-beta (Aβ) positron emission tomography (PET) scans were also performed. Between-group comparisons were estimated using risk ratios (RR) for categorical variables, and mean differences or median regression coefficients for continuous variables. CMB were present in 30% of the DLB participants, with a lobar predominance observed. DLB with CMB were more likely to be on antithrombotic therapy (100%), compared to those without CMB (43%; RR 2.33 [95% CI 1.27, 4.27]). Those with CMB were also more likely to report a history of hypertension (100%) compared to those without (70%; RR 1.75 [95% CI 1.11, 2.75]). DLB core clinical features, cognition and functional status did not differ between the two groups. There was no association found between the presence of CMB and cortical Aβ deposition on PET imaging. CMB are not uncommon in DLB and may be associated with hypertensive small vessel disease. Further studies into the pathophysiology and clinical implications of CMB in DLB are needed. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31092 | DOI: | 10.1016/j.parkreldis.2022.10.009 | Journal: | Parkinsonism & Related Disorders | PubMed URL: | 36252391 | Type: | Journal Article | Subjects: | Cerebral microbleeds Cerebrovascular disease Dementia Dementia with Lewy bodies |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.